sepsis

The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.

Immunexpress received US clearance for a direct-from-blood sepsis test in 2017 and recently won a contract to commercialize a sample-to-answer sepsis assay.

The RT-qPCR-based assay, which has 510(k) clearance, is designed to rapidly differentiate sepsis from systemic inflammatory response syndrome.

The new regulatory approvals add to previous approvals in Singapore, expanding the firm's reach in the Association of Southeast Asian Nations region.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.

With a DNA methylation atlas and deconvolution algorithm, researchers are attempting to trace cfDNA back to tissue sources in healthy or ill individuals.